Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 17/20 | 0.47 |
| ▸ | JAK2 | O60674 | 16/20 | 0.47 |
| ▸ | TYK2 | P29597 | 15/20 | 0.47 |
| ▸ | JAK3 | P52333 | 14/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 2/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13738710 | 0.66 | PRKCI (0.43) | JAK1JAK2TYK2JAK3PRKCI | |
| SCHEMBL3787340 | 0.64 | HTT (0.49) | JAK2JAK3KDM4EMEN1CYP1A2 | |
| SCHEMBL13737660 | 0.64 | JAK1 (1.00) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL31212696 | 0.63 | CYP1A2 (0.44) | KDM4EMEN1CYP1A2ALPGKMT2A | |
| SCHEMBL23505912 | 0.62 | PRKCI (0.43) | JAK1JAK2TYK2JAK3KDM4E | |
| SCHEMBL16664208 | 0.60 | HTT (0.49) | KDM4EMEN1CYP1A2ALPGKMT2A | |
| SCHEMBL12612922 | 0.59 | PRKCI (0.40) | JAK1JAK2JAK3PRKCIAXL | |
| SCHEMBL31038794 | 0.58 | CYP1A2 (0.36) | KDM4EMEN1CYP1A2ALPGKMT2A | |
| SCHEMBL1504325 | 0.58 | PRKCI (0.52) | JAK1JAK2TYK2JAK3PRKCI | |
| SCHEMBL2240671 | 0.58 | AURKB (0.71) | JAK2JAK3PRKCIAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120330012-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2012149280-A2 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120330012-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | JAK1 1096/4885JAK2 346/4885TYK2 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.